Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease | Zendy

Stuart M. Sprague | Zendy; Arnold L. Silva | Zendy; Fahd Al-Saghir | Zendy; Radhika Damle | Zendy; Samir P. Tabash | Zendy; Martin Petkovich | Zendy; Eric J. Messner | Zendy; Jay A. White | Zendy; Joel Z. Melnick | Zendy; Charles W. Bishop | Zendy

Open Access

Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease

Author(s) -

Stuart M. Sprague,

Arnold L. Silva,

Fahd Al-Saghir,

Radhika Damle,

Samir P. Tabash,

Martin Petkovich,

Eric J. Messner,

Jay A. White,

Joel Z. Melnick,

Charles W. Bishop

Publication year - 2014

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000369939

Subject(s) - calcifediol , medicine , secondary hyperparathyroidism , vitamin d and neurology , hyperparathyroidism , kidney disease , placebo , parathyroid hormone , endocrinology , vitamin d deficiency , cholecalciferol , urology , gastroenterology , pathology , calcium , alternative medicine

Vitamin D insufficiency drives secondary hyperparathyroidism (SHPT) and is associated with increased cardiovascular mortality in patients with chronic kidney disease (CKD). SHPT is poorly addressed by current vitamin D repletion options. The present study evaluated a novel investigational vitamin D repletion therapy: a modified-release (MR) formulation of calcifediol designed to raise serum 25-hydroxyvitamin D in a gradual manner to minimize the induction of CYP24 and, thereby, improve the SHPT control.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research